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Abstract 
Introduction: In Hungary, where MMR vaccine coverage is 99%, in 2017, a minor measles epidemic 
started from imported cases due to two major factors – latent susceptible cohorts among the 
domestic population and the vicinity of measles-endemic countries. Suspended immunization 
activities due to the COVID-19 surge are an ominous precursor to a measles resurgence.  This 
epidemiological demonstration is aimed at promoting a better public understanding of 
epidemiological data. 
Materials and Methods: Our previous MMR sero-epidemiological measurements (N of total measles 
cases = 3919, N of mumps cases = 2132, and N of rubella cases = 2132) were analyzed using open-
source epidemiological data (ANTSZ) of a small-scale measles epidemic outbreak (2017, Hungary). 
A simplified SEIR model was applied in the analysis. 
Results: In case of measles, due to a cluster-specific inadequacy of IgG levels, the cumulative 
seropositivity ratios (measles = 89.97%) failed to reach the herd immunity threshold (HIT Measles = 
92–95%). Despite the fact that 90% of overall vaccination coverage is just slightly below the HIT, 
unprotected individuals may pose an elevated epidemiological risk. According to the SEIR model, 
≥74% of susceptible individuals are expected to get infected. Estimations based on the input data of 
a local epidemic may suggest an even lower effective coverage rate (80%) in certain clusters of the 
population. 
Conclusion: Serological survey-based, historical and model-computed results are in agreement. A 
practical demonstration of epidemiological events of the past and present may promote a higher 
awareness of infectious diseases. Because of the high R0 value of measles, continuous large-scale 
monitoring of humoral immunity levels is important. 
 
(Böröcz K, Markovics Á, Csizmadia Z, Najbauer J, Berki T, Németh P. Imported Infections Versus Herd 
Immunity Gaps; A Didactic Demonstration of Compartment Models Through the Example of a Minor 
Measles Outbreak in Hungary. SEEMEDJ 2021; 5(1); 1-16) 
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Introduction 
Testing of acquired immunity and effectiveness 
of vaccination against infectious diseases has 
been increasingly important in the design of 
preventive public health strategies. Resurgence 
in measles cases in the United States and across 
Europe has occurred, including in individuals 
vaccinated with two doses of the vaccine (1). 
According to the Centers for Disease Control 
and Prevention (CDC), World Health 
Organization (WHO) and United Nations 
International Children’s Emergency Fund 
(UNICEF), measles has already been a global 
issue and now it has been aggravated by 
disrupted immunization protocols due to the 
COVID-19 pandemic (2–5). All six WHO regions 
have reported disrupted immunization activities, 
with major adverse effects on routine 
immunization and mass vaccination campaigns 
(4). According to CDC reports, in 2020, more than 
117 million children were at the risk of missing 
out on measles vaccines as a consequence of 
the COVID-19 surge (2). Measles immunity gaps 
resulting from suspended immunization 
activities are an ominous precursor to a measles 
resurgence (4). In Ukraine, one of Hungary’s 
neighboring countries that was already endemic 
for measles, vaccination has been interrupted in 
many regions (3). Regarding Europe, ECDC 
surveillance data have indicated an 
exceptionally high number of measles cases in 
2018, 2019 and 2020 in EU/EEA countries.  
Vaccination remains one of the safest and most 
effective interventions available in public health 
for the primary prevention of infectious diseases, 
resulting in both direct and indirect immunity in 
individuals vaccinated (herd immunity) (6–8). 
Even though a safe and effective two-dose 
measles/MMR vaccination schedule has been 
available in Europe since the 1960s, maintaining 
high vaccine coverage is still difficult, despite 
the fact that in Hungary, the MMR vaccine is 
mandatory and consequently the vaccine 
coverage is estimated to be at 98-99%. 
According to our previous publications (9,10) and 
in agreement with the results obtained by our 
colleagues (11), there are latent immunization 
gaps in certain age (or immunization) clusters of 
the Hungarian population, with predominance of 
the ~35-45-year-old adults. These are 
individuals who form a significant portion of the 
active labor force of the country, for instance 
health care workers (HCWs).  
Between January 2017 and May 2019, there were 
76 reported measles cases in Hungary (12), 54 of 
which were reported between 21 February and 
22 March 2017 (13). Because of the recent 
outbreaks worldwide, not only of measles, but 
also mumps and rubella (MMR) infections, and 
because of waning of immunity over time after 
vaccination (14–17), the importance of 
continuous MMR seroepidemiological screening 
is evident. 
Suboptimal vaccine effectiveness in certain 
clusters of the population has a negative impact 
on overall vaccination coverage. Small-scale 
outbreaks suggest that certain measles 
vaccines – applied during the early phases of the 
Hungarian vaccination history – failed to elicit 
the desired immunological response. The 
resulting immunization gap(s) raise the concern 
of potential further outbreaks (9,11). The 2020 
COVID-19 outbreak called attention to the 
importance of mathematical modelling of 
epidemics (18). Based on a reliable model, the 
timescale and economic impact of the disease 
can be predicted and preventive 
countermeasures can be taken (19). Through the 
example of the measles epidemic in Makó (2017, 
southeast Hungary), we demonstrated that, in 
possession of key epidemiological data (e.g. R0 
value, estimated vaccination coverage of a given 
population, number of infected and recovered 
individuals and duration of the epidemic), a 
simple open-source mathematical model can 
give a good approximation of the course of an 
infection and may provide better general 
compliance with protective measures. 
Materials and Methods  
Experimental work 
In this seroepidemiological survey, we 
combined the data from our previous findings 
with recent measurements, including anti-
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measles, -mumps and -rubella antibody level 
(IgG) determination. Measurements were 
performed on the automated Siemens BEP 2000 
Advance® platform (Siemens AG, Germany), 
using our self-developed ELISA assays 
validated by well-established commercial kits, 
as previously described (9,10). Indirect 
immunofluorescent microscopy was used a 
reference (Euroimmun, Germany).  
In case of large-scale seroepidemiological 
measurements, a serum bank consisting of 
anonymous patient sera was used (N of total 
measles cases = 3919, N of mumps cases = 2132, 
and N of rubella cases = 2132) (Ethical License 
number 2015/5726). Nationally representative 
samples included randomly selected clinical 
residual samples, with the exclusion criteria of 
neonates, children under the vaccination age 
and severely immunocompromised patients. 
Samples were collected from the Department of 
Laboratory Medicine (University of Pécs, Clinical 
Centre). Serum samples were from all listed age 
groups participating in this study and they were 
categorized based on past changes introduced 
in measles and MMR immunization schedules. 
Age group determination was based on the 
landmarks in the history of measles and MMR 
vaccination schedules in Hungary (Figure 1). 
Human sera were stored in the accredited 
laboratory of the Department of Immunology 
and Biotechnology (University of Pécs, Medical 
School, Pécs, Hungary) according to quality 
assurance criteria (ISO 17025). 
Population-level result evaluation and 
seropositivity ratio assessment was performed 
in relation to the concept of herd immunity 
threshold (HIT) values (HIT Measles = 92–95%, 
HIT Mumps = 85–90%, HIT Rubella = 83–86). The 
study relies on the full virus antigen repertoire-
based indirect ELISA method. Therefore, it must 
be considered a good surrogate, rather than an 
absolute correlate marker for immunity – as far 
as Plotkin’s nomenclature is considered 
normative (20–22). We examined vaccination 
group-related infection- and vaccine-induced 
antibody titres using the following software: 
SPSS, Origin Pro, Excel. 
SEIR model example and input data  
A small-scale measles outbreak in Hungary in 
2017 raised questions about the vaccination 
coverage rate in the country. Experimental 
results supported the theory of ineffective 
vaccines, as previously mentioned (9). In spite of 
its limitations, it seemed reasonable to set up a 
SEIR model calculation in order to see whether 
a few percent decrease in effective vaccination 
could result in a local epidemic. To demonstrate 
the disease spread in a well-immunized 
population where latent immunity gaps may be 
present, input data were based on the data of 
the 2017 measles outbreak in Makó, southeast 
Hungary. The following parameters were used 
to perform the calculations: 
Population (N): The epidemic was linked to the 
small-town hospital. During that year, 65 
physicians were responsible for medical 
attendance of the estimated 30,000 inhabitants 
of Makó and the surrounding villages. In our 
model, a population of N = 400-1,000 people 
was assumed, including patients, health-care 
workers and family members. 
Number of infected individuals (I): A total of 29 
cases were reported. 
Incubation time and contagious period: The 
incubation time for measles ranges from 10 to 12 
days on average, an infected person can be 
contagious even 1-2 days before the first 
characteristic symptoms are visible, up to 4 days 
after the rashes appear. In our model, the 
incubation time (Tinc) was assumed to be 10 
days, whereas the contagious period (Tcont) 
parameters were determined by equations (5) 
and (6). 
Reproduction rate ranging from 12 to 18 can be 
found in the literature and both values were 
tested. The higher value is applicable to 
communities where no social distancing is 
present and the ratio of vaccinated or 
immunized inhabitants is low. In Central Europe, 
the use of the lower value seems more rational, 
although this specific epidemic was kept mainly 
in a hospital, where circumstances promote the 
spread of the infection. In this case, the start of 
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the outbreak was defined as the possible first 
day of the first patient’s infection, while the 
model was set to stop after the recovery of the 
last infected person. When it comes to large-
scale epidemics, a different approach is used. If 
no new cases are found after a certain period, 
the outbreak is over. This time period is usually 
determined by the incubation time, with a 
calculation method suggested by the WHO. 
Based on the ELISA antibody measurements, it 
can be assumed that only ~90% of the Hungarian 
population has effective immunization, which is 
under the theoretical 92-94% of HIT. In the 
model, 90% of seroprevalence was assumed, 
but lower values were also tested subsequently. 
No additional vaccinated (V) compartment was 
created and immunized individuals were treated 
as recovered. Vital dynamics was disregarded 
due to the short period of the epidemic. Death 
rate was not taken into consideration either, as 
no fatalities were observed during the 
Hungarian outbreak. Calculations were 
performed using Microsoft Excel Visual Basic 
Application (VBA), but the graphs were plotted in 
Origin. VBA is a built-in feature of the Microsoft 
Office Suite with several limitations, but its 
prevalence and the user-friendly computer 
language makes it suitable for educational 
purposes. 
Results 
Changes and historical data regarding 
epidemics in the Hungarian measles/MMR 
vaccination schedule (23–25) have been plotted 
on a timeline in order to evaluate 
seroepidemiological data accordingly. Figure 1 
shows changes in measles and MMR vaccination 
schedules in Hungary since the introduction of 
the vaccine (1969). High age-specific attack rates 
characterizing major epidemics (1980-81 and 
1988-89) along with 93%-99% of vaccine 
coverage evidence insufficiencies of the early 
vaccination program. 
 
Figure 1. Measles and MMR vaccination schedules in Hungary 
(a) Vaccination against measles was introduced in Hungary in 1969. (b) From 1969 to 1974, a single dose of measles 
vaccine was administered in mass campaigns to persons aged 9-27 months. (c) After vaccination was 
implemented, the incidence rate decreased until 1973-74, when large epidemics occurred primarily in 
unvaccinated 6-9-year-olds. (d) The recommended age for vaccination was 10 months until 1978, when it was 
changed to 14 months. (e) After the 1980-81 epidemic, persons born between 1973 and 1977, who received vaccine 
when the recommended age was 10 months, were revaccinated. (f) The 1988-89 epidemic mainly affected persons 
aged 17-21, who had been targeted to receive vaccine during mass campaigns in the first years of the vaccination 
program in Hungary. After 1989, children were re-vaccinated at the age of 11 with a monovalent measles vaccine 
in a scheduled manner. Also, in 1989, the rubella vaccine was introduced. (g) In 1990, measles-rubella bivalent 
vaccines were introduced. (h) The administration of the first vaccine at the age of 14 months lasted from 1978 to 
1991. Also, in 1991, the measles-mumps-rubella trivalent vaccine was introduced. (i) In 1992, the administration of 
the first MMR vaccine was shifted to 15 months of age. (j) In 1996, the MERCK MMR II vaccine (Enders’ Edmonston 
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strain, live attenuated) was introduced. (k) In 1999, measles-mumps-rubella revaccination replaced the monovalent 
measles vaccine. Also, in 1999, the GSK PLUSERIX vaccine (Measles Schwarz Strain) was introduced. (l) In 2003, the 
GSK PRIORIX vaccine was introduced. (m) Between 2004 and 2005, the MERCK MMR II vaccine was used. (n) 
Between 2006 and 2010, the GSK PRIORIX vaccine was in use. (o) Starting from 2011, we have been using a Sanofi-
MSD product, MMRvaxPro (Measles virus Enders’ Edmonston strain, live, attenuated), for vaccination and 
revaccination of children. GSK PRIORIX is still on the market, commonly used for vaccination in adulthood. (p) 
Between January 2017 and December 2019, there were 76 reported measles cases in Hungary (according to ECDC 
Surveillance reports). (Source of information: MMWR Weekly October 06, 1989 / 38(39); 665-668, International 
Notes Measles – Hungary, http://www.vacsatc.hu, https://www.ecdc.europa.eu) 
 
Figure 2 shows the age or vaccination group-
specific seropositivity and seronegativity ratios 
for measles, mumps and rubella. The lowest 
seropositivity ratios in terms of anti-measles 
antibody titres (IgG) were observed in the groups 
‘Vaccinated between 1969-1977’ (87.56%) and 
‘Vaccinated between 1978-1987’ (78.48%). These 
results are further confirmed by the 
abovementioned vaccine insufficiencies of the 
relative periods, described in Figure 1. Regarding 
the mumps and rubella seroepidemiological 
survey, in terms of humoral antibody levels, all 
vaccination groups satisfied the requirements 














Figure 2. Measles, mumps and rubella 
seropositivity ratios according to vaccination 
groups 
Age / vaccination groups: (I) Individuals born before 
1969. (II) Individuals vaccinated between 1969 and 1977. 
(III) Individuals vaccinated between 1978 and 1987. (IV) 
Individuals vaccinated between 1988 and 1990. (V) 
Individuals vaccinated between 1991 and 1995. (VI) 
Individuals vaccinated between 1996 and 1998. (VII) 
Individuals vaccinated between 1999 and 2002. (VIII) 
Individuals vaccinated in 2003. (IX) Individuals 
vaccinated between 2004 and 2005. (X) Individuals 
vaccinated between 2006 and 2010 (XI) Individuals 
vaccinated after 2011. The lowest seropositivity ratio 
(78.48%) was observed in the anti-measles antibody 
titres (IgG) in the group ‘Vaccinated between 1978 and 
1987’. 
In case of measles, mumps and rubella 
cumulative results, the seropositivity ratios were 
89.97%, 91.60% and 92.58%, respectively, as 
shown in Figure 3. Due to previously detailed 
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cluster-specific inadequacy of humoral antibody 
levels, the cumulative anti-measles 
seropositivity ratios also failed to reach the herd 
immunity threshold (HIT Measles = 92–95%).
 
Measles Mumps Rubella 
   
 Overall seropositivity ratio  
 Overall seronegativity ratio  
𝑆𝑒𝑟𝑜𝑝𝑜𝑠𝑖𝑡𝑣𝑖𝑡𝑦 𝑟𝑎𝑡𝑖𝑜 = 𝑇𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑠𝑎𝑚𝑝𝑙𝑒𝑠 −
𝛴 (𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒 + 𝑒𝑞𝑢𝑖𝑣𝑜𝑐𝑎𝑙 𝑠𝑎𝑚𝑝𝑙𝑒𝑠)
𝑇𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑠𝑎𝑚𝑝𝑙𝑒𝑠
∗ 100 
HIT Measles = 92–95% HIT Mumps = 85–90% HIT Rubella = 83–86% 
Figure 3. Overall seropositivity and seronegativity ratios 
N measles = 3,919; N mumps, rubella = 2,132. In case of measles, mumps and rubella cumulative results, the 
seropositivity ratios were 89.97%, 91.60% and 92.58%, respectively. The overall ratio of seropositive samples was the 
lowest in the ‘measles’ group, where it remained under the threshold value. Seropositivity ratios were calculated as 
follows: 
Using the seronegativity ratio of 89.97% (≈ 90%) 
obtained by the cumulative data representation 
of anti-measles (IgG) antibody levels, the model 
of possible outcomes of a measles outbreak in a 
hospital as a function of the vaccination 
coverage rate was investigated. The results of 
the VBA-based SEIR model of the 2017 epidemic 
in Hungary are summarized in Table 1. Three 
parameters – population of the sample, ratio of 
immunized individuals and reproduction rate of 
the virus – were set to different values. The 
effect of these adjustments was investigated 
and changes in the number of measles cases 
and timescale of the epidemic were observed. 







Population of the 
sample (N) 
Ratio of immunised 
(%) 
Total number of 
measles cases 
Duration of epidemic 
𝑹𝟎 = 𝟏𝟖 
1000 90 73 6 months 
400 90 29 4 months 
400 80 78 3 months 
150 80 29 2.5 months 
𝑹𝟎 = 𝟏𝟐 
1000 90 2 6 days 
400 90 2 6 days 
400 80 70 4 months 
150 80 26 3 months 
Empirical values 
? 90 29 2 months 
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At R_0=18 and N = 1000, assuming 90% effective 
vaccination, 100 susceptible individuals can be 
found in the population. The model estimates a 
total number of infected persons at 74 and the 
duration of the epidemic at half a year, which is 
more than double of the real values. By setting 
the population at N = 400, 30 infected individuals 
and 4 months were given by the model. This way 
the number of infected persons corresponds to 
the actual clinical data, but the duration is still 
longer compared to empirical findings.  
Timescale of the epidemic can be compressed 
by increasing the proportion of susceptible 
people. If the vaccination coverage rate is 
changed from 90% to 80%, the duration of the 
epidemic is reduced to 3 months, but the total 
number of infected individuals becomes higher. 
Based on this anomaly, it can be presumed that 
the total number of involved population might 
be even lower than 400. Unfortunately, the 
results of the contact tracing procedure were 
not available for a better approximation.  
An acceptable correspondence between the 
model calculations and the clinical data was 
observed by assuming N = 150 and 80% of 
vaccination coverage as input parameters. 
The results – 30 infections in a two-month period 
– are close to the official values. For a better 
comparison, modelling with R_0=12 was also 
performed. The less contagious the virus, the 
fewer cases are found. Using this lower 
reproduction rate, only isolated cases can occur 
at 90% of vaccination coverage (which is a value 
that resembles the HIT). By decreasing the 
vaccination rate, the number of cases increases 
and the timescale is shortened, similarly to 
previous test examples. 
 
Discussion 
MMR vaccination in Hungary  
In Hungary, MMR vaccine is mandatory. A single-
dose, live-virus combined measles-mumps-
rubella (MMR) vaccine is used to vaccinate 
infants of ≥15 months of age. A reminder vaccine 
is given to sixth year primary school students (~11 
years of age). PRIORIX (GSK), PRIORIX-TETRA 
(GSK), ProQuad (MERCK) and the M-M-
RVAXPRO (MSD Pharma) vaccines are currently 
used in Hungary for vaccination of children (at 15 
months and 11 years of age) and for adults (62). 
The vaccines contain live attenuated viruses (26). 
Regarding insufficient cumulative anti-measles 
seropositivity levels, we would like to emphasize 
that potential gaps in the population-level 
humoral immunity (IgG) are attributable to early 
vaccination periods and are not a general 
phenomenon relative to the current 
immunization practices. The susceptibility of 
certain cohorts is likely attributable to the 
thermal instability of the historical Leningrad-16 
vaccine, inefficient seroconversion owing to 
vaccination at a premature age (e.g. 9 months of 
age) and the questionable efficiency of the 
inoculum itself (9, 11, 25, 29, 30, 31). The 2017 
measles outbreak in Makó was provoked by 
imported cases. Some of our bordering 
countries are still endemic for measles (27–30). 
Supplementary Figure 1 shows the European 
measles cases in the time period relative to the 
epidemics in Makó and Szeged. COVID-19 is 
increasing the risk of measles outbreaks. 
According to CDC Global Measles Outbreak 
reports of January 2021, 41 countries may 
postpone their measles campaigns for 2020 or 
2021 due to the COVID-19 pandemic. This 
increases the risk of bigger outbreaks around 
the world (31).
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Supplementary Figure 1. European measles cases in the time period relative to the epidemics in 
Makó and Szeged (ecdc.europa.eu) 
Between December 2016 and November 2017, numerous measles cases occurred in Europe, most of which were 
reported by Romania, one of Hungary’s neighbouring countries. Source of data: https://www.ecdc.europa.eu/ 
 
2017 measles epidemic in Hungary 
In 2017, according to the data of the national 
authorities, a total of 76 persons were infected 
with measles (corrected to 73 laboratory 
confirmed cases by ECDC Surveillance reports). 
The outbreak in the hospital of the small town of 
Makó involved 29 individuals and lasted from 
January 2017 to March 2017 (32,33).  In order to 
demonstrate the spread of virus in a well-
immunized population, where despite good 
vaccination coverage, latent immunization gaps 
(unprotected, seronegative cohorts) are present, 
we used an open-source epidemiological report 
of the Hungarian National Public Health and 
Medical Officer Service (ANTSZ) (17 March 2017): 
‘At the peak of the Hungarian measles 
epidemics during the spring of 2017, 52 cases 
with measles-specific symptoms were reported. 
Of these, 15 laboratory confirmed cases 
(National Reference Laboratory for Measles and 
Rubella, National Public Health Institute, 
Budapest, Hungary) were registered by 16 
March. Of these patients, 12 were health care 
workers (HCWs) and two were hospitalized 
































































Measles cases by notification rate (ECDC)
(December 2016 - November 2017; cumulated results)
Laboratory confirmed case Cases
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other one was a patient living in the vicinity of a 
HCW. The epidemic affected two health care 
institutions, the Hospital of Makó and the clinics 
of the University of Szeged. The first measles 
case was imported in mid-February 2017 to the 
Hospital of Makó. The epidemic affected the 
hospital staff and their contacts. By 17 March, a 
measles infection was confirmed in case of a 
patient who was presumed to be the original 
importer of the virus, in case of 11 HCWs and in 
case of one of the HCW’s contacts. At the time 
of this report, additional 11 cases (of which seven 
HCWs and three patients’ contacts) were still 
under investigation. At the clinics of the 
University of Szeged, two persons – a HCW and 
a patient – fell ill with measles. Another 11 
persons (six patients and five HCWs) were also 
suspected at the time of the report. Following 
the appearance of the abovementioned 
measles cases, in Csongrád County, a total of 
391 people were vaccinated against measles, 
mumps and rubella (MMR). As the first cases of 
this period had been revealed, the National Chief 
Physician ordered strict monitoring and 
reporting of suspected measles virus infections. 
Thus, another 15 suspected cases were 
registered in several other counties. At the time 
of the report, laboratory testing was still ongoing 
(12)’. 
The second group of imported cases was 
detected at the end of July 2017 in Nyíregyháza, 
Szabolcs-Szatmár-Bereg County, Hungary (11). 
Six unvaccinated Romanian children were 
hospitalised with clinical symptoms of measles. 
These cases were later laboratory confirmed 
(National Reference Laboratory for Measles and 
Rubella, National Public Health Institute, 
Budapest, Hungary). The subsequent disease 
spread among two additional HCWs (also 
laboratory confirmed) supports the 
susceptibility of certain clusters in the Hungarian 
population (11). 
Epidemiological model- a didactic representation 
In this section, we explain the spreading 
mechanism of infectious diseases for those who 
are not familiar with the computational 
background of modelling. To understand the 
basics of epidemic models, a simplified 
mathematical interpretation can be used. The 
spread of a disease can be described by S-
shaped sigmoid mathematical functions, similar 
to the well-known pH titration curve, or 
haemoglobin saturation curves. As infectious 
diseases spread from human to human, the 
number of susceptible persons is decreasing 
over time and it influences the propagation of 
the pathogenic agent. In the beginning of the 
outbreak, the damping effect of recovered 
patients is minimal; the curve is very close to 
exponential and the number of new cases 
increases rapidly. At a certain time, a kind of 
equilibrium follows, daily recoveries can balance 
new infections and the curve reaches its 
inflection point. Afterwards, in the saturation 
phase, the epidemic slows down and at the end, 
no new cases are found and the vast majority of 
the population has recovered (Figure 4). The 
curves represented in Figure 4 are a graphic 
interpretation of a commonly used method for 
epidemic modelling – the compartment model. 
In this model, the population is divided into 
compartments – well-defined categories based 
on their epidemiological properties. In a 
compartment, all individuals behave exactly the 
same, e.g. they are all infected, all vaccinated, all 
exposed, etc. The simplest among these 
compartment models is the SIR model, where 
the letters of the acronym stand for susceptible, 
infectious and recovered. 
.
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Figure 4. SIR model curves of a hypothetical 
epidemic 
As the disease spreads, the number of susceptible 
individuals decreases. First they get infected (I), but 
later on they will progress to the recovered 
compartment (R). Approximately 6% of the population 
managed to avoid contact with infected individuals. 
The peak of infections could be observed almost three 
months after the first case was recorded, affecting 8% 
of the population at the same time. 
The progression of an individual in this model is 
easy to follow, each member of the population 







Transition between compartments is described 
probability of transmitting the disease between 
a susceptible and an infectious person. In other 
individuals to whom an infectious person can 
pass the disease per day (18,39,40) For example, 
if the infection rate is 0.2, it will take five days on 
average to infect someone. If we assume that 
the patient is contagious for 10 days, two new 
infections are expected in this case.  
The overall efficacy of the epidemic can be 
described by the number of these secondary 
infections originated from the primary infection, 
our first patient. This important parameter is the 
basic reproduction number (R0). Each virus has 
its own average R0 value – 12-18 for measles 
and 3.3-5.7 for COVID-19, according to the 
literature. 
transition into the recovered compartment. For 
instance, if this rate is 0.1, the contagious period 
will last for 10 days.  
From a mathematical perspective, the 
transitions can be described by the following 
differential equations, where S, I and R are the 
number of individuals in the corresponding 
















Mathematical methods (such as the Runge-
Kutta method) are available for solving similar 
equations, but there is a simpler option. Using 
the built-in features of Microsoft Excel (or any 
equivalent spreadsheet application), it is 
possible to make calculations using an iterative 
method. Instead of solving the equations, the 
computer performs calculations that follow the 
daily changes in different compartments. 
R0 have to be defined. Based 
on the definition of the transition rates, it can be 
seen that the recovery rate can be determined 












Let us assume that in a certain population 
measles can be transmitted from a single person 
to 12 others (R_0=12) and they stay contagious for 
6 days (T_cont=6). In this case: 
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𝛽 = 𝑅0𝛾 = 2 (8) 
Incubation time plays an important role in the 
spread of a disease. In a more sophisticated 
model (SEIR model), this can also be taken into 
consideration. A new compartment for the 
exposed part of the population can be 
generated. The susceptible person first gets 
exposed and will progress to the infectious state 








The parameter ‘α’ is a new transition rate, 
which can be determined by the incubation time 





New compartments can be added to the model 
anytime, such as the compartment M for 
individuals with maternal immunity or the 
compartment E for exposed individuals, who are 
already infected, but not infectious. Based on the 
characteristics of certain infectious diseases, 
further models have been developed, such as 
the SIS, MSIR, SEIR, SEIS, MSEIR and MSEIRS 
models. The second ‘S’ in the acronym indicates 
that after the infection, no permanent immunity 
can be reached and the individuals step to the S 
compartment again. In other models, the ratio of 
hospitalization, the ratio of mild and severe 
cases and epidemiological interventions can be 
included, with a more complex mathematical 
background. 
In the examples described above some 
important parameters are simply disregarded, 
although it is possible to perform a more 
detailed computation. Vital dynamics, the 
natural dynamics of birth and death, can be 
included by adding two further parameters.  
It is necessary to mention that compartment 
models have their well-known limitations and 
shortcomings. For instance, all individuals in the 
population are assumed to have an equal 
probability of coming in contact with others, 
although society is inhomogeneous from the 
perspective of social distancing. Another 
drawback is that the traditional compartment 
model cannot handle uncertainty in model 
parameters. Working with a smaller set of data 
increases this uncertainty, making predictions 
unreliable. To overcome this problem, it is usual 
to calculate the SIR model over a few possible 
values for each parameter. A more complex 
solution is to use distribution functions instead of 
single numbers and if real-time data is available 
(e.g. we are in the middle of a pandemic), a 
clinical dataset can be utilized to adjust these 
parameters (36–38). 
Regarding the SEIR model resembling the 2017 
measles outbreak in Makó (Figure 4), we would 
like to note that both the simplified 
mathematical method and the input data were 
unreliable. With more sophisticated models, 
many different parameters can be taken into 
consideration (37,39). Despite that fact, the 
calculated values correspond in order of 
magnitude to the available data on the epidemic 
and support the experimental results describing 
the vaccination gap.  
Model curves using a lower percentage of the 
population-level anti-measles protection rate 
are more fitting. This finding may indicate an 
even lower percentage of effectively vaccinated 
population than it was found previously (~90%).  
It is concluded that the importance of 
seroepidemiological surveys is confirmed by the 
recent outbreaks of measles, mumps and 
rubella infections in several countries 
(14,16,17,40–45). Considering the HIT values, 
suboptimal anti-measles seropositivity ratios 
were detected in certain clusters of the early 
vaccination era (78.48% of sufficient anti-
measles IgG antibody titres among individuals 
vaccinated between 1978 and 1987). This finding, 
which is in accordance with a recent study 
published by our colleagues (11) and historical 
literature data (46), suggests the existence of 
age-specific immunization gaps in the 
Hungarian population. For mumps and rubella, 
our preliminary data shows satisfactory 
immunity levels. Nowadays, in our country, the 
MMR vaccination coverage is ideal due to the 
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mandatory administration of safe and modern 
trivalent vaccines. Nevertheless, dubious 
immunization practices in some of our 
neighboring countries, aggravated by the 
detrimental effect of the COVID-19 pandemic 
and subsequent suspension of measles 
vaccination campaigns, may facilitate the 
occurrence of minor importation-related MeV 
outbreaks in susceptible cohorts. Using the 
example of the 2017 measles outbreak in Makó, 
it has been demonstrated that in possession of 
key epidemiological parameters (e.g. R0 value, 
estimated vaccination coverage of a given 
population, number of infected and recovered 
individuals, duration, etc.), a simple SEIR model 
can give a good approximation regarding the 
course of an infection.  
We believe that awareness may significantly 
reduce the extent of an epidemic (38,47). In the 
light of current disquieting epidemiological 
circumstances, we suggest the introduction of 
open-access mathematical and epidemiological 
models into modern natural science education 
of students. Today, online epidemic models are 
easily available for the public (35,36). Practical 
introduction to these plain calculation models 
could help students understand the rationale 
behind epidemiological data. We believe that a 
practical demonstration of epidemiological 
events can promote a better understanding of 
countermeasures and also allow for an easier 
adaptation to the current epidemiological 
regulations. 
Limitations of experimental work 
The diagnostic ability of our assay was 
calculated based on the results obtained by 
well-established kits capable of humoral 
antibody detection, rather than on neutralizing 
antibody titres that could serve as an absolute 
correlate of protection (48–50). It is important to 
emphasize that immunity to measles is a 
complex orchestration between the cellular and 
humoral immunity. For this reason, only 
antibody-based definitions of vaccine success 
and failure may be misleading, or at least 
simplistic and incomplete (51). 
Limitations of mathematical modelling 
Input data plays a key role in modelling of 
epidemics. Even when the number of cases is 
high – like in the 2020 COVID outbreak – the 
confidence of fitting is poor at the beginning of 
new cases vs. time graph. The first cases are 
usually unexpected, quarantine and social 
distancing protocols are not applied yet and if 
the disease has a low prevalence in the 
population, the accuracy of the diagnosis might 
be low. Besides that, atypical symptoms can be 
misleading for physicians. Furthermore, 
statistical values, such as basic reproduction 
number, incubation and recovery time, depend 
on other factors, such as social distancing and 
the health care system. 
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